The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., Oct. 15, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott’s largest business. In addition […]
SAN DIEGO, Sept. 25, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company’s Portico™ transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aortic stenosis – a life-threatening narrowing […]
SAN DIEGO, Sept. 23, 2018 /PRNewswire/ — Abbott (NYSE :ABT ) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or a leaky heart […]
ABBOTT PARK, Ill., July 26, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation. The trial will evaluate the safety […]
ABBOTT PARK, Ill., July 18, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2018. Second-quarter worldwide sales of $7.8 billion increased 17.0 percent on a reported basis and 8.0 percent on an organic* basis. Reported diluted EPS from continuing […]
ABBOTT PARK, Ill., July 12, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart […]
PARIS, May 23, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and […]
ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE stents are among the […]
PARIS, May 22, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott’s fractional flow reserve (FFR) […]
ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, […]
